Imugene Ltd
Company Profile
Business description
Imugene Ltd is an Australian-headquartered clinical stage cell therapy company developing an Allogeneic CAR T for blood cancers. Its lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. The lead asset, azer-cel, is an allogeneic CAR T cell therapy targeting CD19 positive cancer cells. Autologous CAR T therapies, which use the patient's own modified T cells, azer-cel uses donor-derived T cells that are genetically engineered to attack cancer cells. The group has identified one reportable segment, being the research and development of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUST: +61 294230881
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
5
Stocks News & Analysis
stocks
Samsung and SK Hynix lead chip selloff as China competition fears grow
stocks
Updating our assumed commodity prices and fair values of the two largest Aussie miners
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,921.50 | 15.50 | -0.17% |
| CAC 40 | 7,827.63 | 5.25 | -0.07% |
| DAX 40 | 25,259.90 | 17.78 | -0.07% |
| Dow JONES (US) | 51,670.10 | 180.45 | -0.35% |
| FTSE 100 | 10,650.33 | 5.95 | -0.06% |
| HKSE | 24,345.22 | 74.02 | 0.30% |
| NASDAQ | 27,204.38 | 41.52 | -0.15% |
| Nikkei 225 | 67,777.52 | 1,253.40 | -1.82% |
| NZX 50 Index | 13,749.60 | 78.02 | -0.56% |
| S&P 500 | 7,805.45 | 1.79 | -0.02% |
| S&P/ASX 200 | 8,783.90 | 0.70 | 0.01% |
| SSE Composite Index | 3,800.86 | 3.62 | 0.10% |